OFFICIAL PUBLICATION OF

by its subsidiary APPco

June MIMS update

01/06/2023

We look at some of the recent changes to the medicines landscape, with new products, new indications and safety related changes New Products Deucravacitinib (Sotyktu) is a small molecule that selectively inhibits the tyrosine kinase 2 (TYK2) enzyme. It binds to the regulatory domain of TYK2, stabilising an inhibitory interaction between the regulatory and the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘Consumer confusion, pharmacist frustration’ if current system continues

I welcome Mark's move, at least someone talks about it. But like any push at the forefront, it comes with…

Benjamyn Sung

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

June MIMS update

Previous It’s a “Transition of Care Stewardship” kind of morning...

Next Kidney damage warning

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous It’s a “Transition of Care Stewardship” kind of morning...

Next Kidney damage warning

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.